These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 830926)

  • 21. [Cystic fibrosis: current therapy. Pancreatic enzyme supplementation].
    Schibli S
    Schweiz Med Wochenschr Suppl; 2000; 122():12S-14S. PubMed ID: 12536463
    [No Abstract]   [Full Text] [Related]  

  • 22. [Modern treatment of mucoviscidosis (cystic pancreatic fibrosis)].
    Rossi E
    Dtsch Med Wochenschr; 1970 Oct; 95(42):2133-5. PubMed ID: 5475493
    [No Abstract]   [Full Text] [Related]  

  • 23. Medium-chain triglyceride absorption in patients with pancreatic insufficiency.
    Caliari S; Benini L; Sembenini C; Gregori B; Carnielli V; Vantini I
    Scand J Gastroenterol; 1996 Jan; 31(1):90-4. PubMed ID: 8927947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical trial of several preparation types of the pancreatic extract Pancrex V in the treatment of cystic fibrosis].
    Braggion C; Mastella G
    Minerva Pediatr; 1985 Nov; 37(21-22):891-6. PubMed ID: 3912659
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
    Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
    J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary intake in children and adolescents with cystic fibrosis.
    Woestenenk JW; Castelijns SJ; van der Ent CK; Houwen RH
    Clin Nutr; 2014 Jun; 33(3):528-32. PubMed ID: 23920501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topics in clinical medicine: treatment of pancreatic insufficiency.
    Iber FL
    Johns Hopkins Med J; 1968 Mar; 122(3):172-9. PubMed ID: 4868819
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of two pancreatin microsphere preparations in cystic fibrosis.
    Elliott RB; Escobar LC; Lees HR; Akroyd RM; Reilly HC
    N Z Med J; 1992 Mar; 105(930):107-8. PubMed ID: 1553114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pancreatic extracts on the faecal excretion and on the serum concentration of cobalamin and cobalamin analogues in cystic fibrosis.
    Gueant JL; Vidailhet M; Pasquet C; Djalali M; Nicolas JP
    Clin Chim Acta; 1984 Feb; 137(1):33-41. PubMed ID: 6697525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uric acid serum concentrations in CF-children after pancreatic enzyme supplementation.
    Wiersbitzky S; Ballke EH; Wolf E; Paul W
    Padiatr Grenzgeb; 1989; 28(3):171-3. PubMed ID: 2761994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of antacid and formulation on effectiveness of pancreatic enzyme supplementation in cystic fibrosis.
    Braggion C; Borgo G; Faggionato P; Mastella G
    Arch Dis Child; 1987 Apr; 62(4):349-56. PubMed ID: 3036018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzyme supplement.
    Durie PR; Newth CJ; Forstner GG; Gall DG
    J Pediatr; 1980 May; 96(5):862-4. PubMed ID: 7365588
    [No Abstract]   [Full Text] [Related]  

  • 34. Uses and abuses of enzyme therapy in cystic fibrosis.
    Durie P; Kalnins D; Ellis L
    J R Soc Med; 1998; 91 Suppl 34(Suppl 34):2-13. PubMed ID: 9709382
    [No Abstract]   [Full Text] [Related]  

  • 35. Nutritional management and pancreatic enzyme therapy in cystic fibrosis patients: state of the art in 1987 and projections into the future.
    George DE; Mangos JA
    J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S49-57. PubMed ID: 3042940
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis.
    Boyle BJ; Long WB; Balistreri WF; Widzer SJ; Huang N
    Gastroenterology; 1980 May; 78(5 Pt 1):950-3. PubMed ID: 7380201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
    Proesmans M; De Boeck K
    Eur J Pediatr; 2003 Nov; 162(11):760-3. PubMed ID: 13680386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary supplement and nutrition in children with cystic fibrosis.
    Berry HK; Kellogg FW; Hunt MM; Ingberg RL; Richter L; Gutjahr C
    Am J Dis Child; 1975 Feb; 129(2):165-71. PubMed ID: 1091138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macronutrient intake in preschoolers with cystic fibrosis and the relationship between macronutrients and growth.
    Filigno SS; Robson SM; Szczesniak RD; Chamberlin LA; Baker MA; Sullivan SM; Kroner J; Powers SW
    J Cyst Fibros; 2017 Jul; 16(4):519-524. PubMed ID: 28185886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperuricemia in cystic fibrosis.
    J Pediatr; 1979 Aug; 95(2):330-1. PubMed ID: 448582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.